Up to 73% of Atopic Dermatitis Patients Taking Lilly’s Lebrikizumab Had Improved or Cleared Skin on Face or Hands in New Analysis New secondary analysis from Eli Lilly and Company’s (NYSE: LLY) Phase 3 clinical development program showed patients receiving lebrikizumab who…
Teva and MedinCell Announce FDA Approval of UZEDY™ (risperidone) Extended-Release Injectable Suspension, a Long-Acting Subcutaneous Atypical Antipsychotic Injection, for the Treatment of Schizophrenia in Adults Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and…
Update on FDA Advisory Committee Vote on LYNPARZA® (olaparib) Plus Abiraterone and Prednisone or Prednisolone in First-Line Metastatic Castration-Resistant Prostate Cancer RAHWAY, N.J.–(BUSINESS WIRE)– Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the…
Update on FDA Advisory Committee vote on Lynparza plus abiraterone for metastatic castration-resistant prostate cancer The Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) has recognised a favourable benefit risk profile for AstraZeneca and MSD’s Lynparza (olaparib) plus abiraterone and…
REGENERON AND ALNYLAM REPORT POSITIVE INTERIM PHASE 1 CLINICAL DATA ON ALN-APP, AN INVESTIGATIONAL RNAI THERAPEUTIC FOR ALZHEIMER’S DISEASE AND CEREBRAL AMYLOID ANGIOPATHY Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) and Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) announced today positive interim results from the ongoing single ascending dose…
CHMP recommends EU approval of Roche’s fixed-duration Columvi (glofitamab) for people with relapsed or refractory diffuse large B-cell lymphoma Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP)…
Bristol Myers Squibb Announces Leadership Transition Plan Bristol Myers Squibb (NYSE: BMY) today announced that Giovanni Caforio, MD, Chairman of the Board and Chief Executive Officer, has decided to retire as Chief Executive Officer, effective November 1, 2023. Christopher Boerner,…
Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for CAMZYOS® (mavacamten) for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (HCM) Bristol Myers Squibb (NYSE: BMY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European…
Boehringer Ingelheim inaugurates the largest European development center for biotechnology Boehringer Ingelheim today inaugurated its state-of-the-art Biologicals Development Center (BDC) in Biberach an der Riß, Germany. The new high-tech facility underlines the company’s strong commitment to Germany and Europe as…
Lilly to Divest BAQSIMI to Amphastar In an effort to continue expanding the availability of BAQSIMI® to patients, Eli Lilly and Company (NYSE: LLY) and Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) have entered into a definitive agreement for Lilly to divest BAQSIMI worldwide to Amphastar, a global pharmaceutical company…
AMGEN ANNOUNCES WEBCAST OF 2023 FIRST QUARTER FINANCIAL RESULTS Amgen (NASDAQ:AMGN) today announced that it will report its first quarter financial results on Thursday, April 27, 2023, after the close of the U.S. financial markets. The announcement will be followed by a conference call…
Welcome to The Pharma Data – Your Gateway to the Global Pharmaceutical Industry. The Pharma Data is an information-centric platform focused on delivering comprehensive coverage of the pharmaceutical industry online. As both a B2B and B2C resource, we are committed…